Neuroprotection with glatiramer acetate: evidence from the PreCISe trial

The phase III, multicenter, randomized, placebo-controlled PreCISe trial assessed glatiramer acetate (GA) effects in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis (MS). To assess the neuroprotective effect of GA in a subset of patients in the PreCISe trial, we us...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Douglas L., Narayanan, Sridar, Antel, Samson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705142/
https://www.ncbi.nlm.nih.gov/pubmed/23589190
http://dx.doi.org/10.1007/s00415-013-6903-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705142/
https://www.ncbi.nlm.nih.gov/pubmed/23589190
http://dx.doi.org/10.1007/s00415-013-6903-5

Ejemplares similares